393 related articles for article (PubMed ID: 30338425)
21. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
22. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
[TBL] [Abstract][Full Text] [Related]
23. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
24. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.
Clark SE; Warwick J; Carpenter R; Bowen RL; Duffy SW; Jones JL
Br J Cancer; 2011 Jan; 104(1):120-7. PubMed ID: 21139586
[TBL] [Abstract][Full Text] [Related]
25. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
26. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
27. High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer.
Gennaro M; Meneghini E; Baili P; Bravaccini S; Curcio A; De Santis MC; Lozza L; Listorti C; Di Cosimo S; Sant M; Folli S
Tumori; 2020 Feb; 106(1):64-69. PubMed ID: 31446852
[TBL] [Abstract][Full Text] [Related]
28. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
29. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
30. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
31. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
[TBL] [Abstract][Full Text] [Related]
32. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
Zhou W; Jirström K; Amini RM; Fjällskog ML; Sollie T; Lindman H; Sørlie T; Blomqvist C; Wärnberg F
BMC Cancer; 2013 Oct; 13():512. PubMed ID: 24171825
[TBL] [Abstract][Full Text] [Related]
33. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
[TBL] [Abstract][Full Text] [Related]
34. Biofunctional characteristics of in situ and invasive breast carcinoma.
Bravaccini S; Granato AM; Medri L; Foca F; Falcini F; Zoli W; Ricci M; Lanzanova G; Masalu N; Serra L; Buggi F; Folli S; Silvestrini R; Amadori D
Cell Oncol (Dordr); 2013 Jul; 36(4):303-10. PubMed ID: 23807750
[TBL] [Abstract][Full Text] [Related]
35. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
36. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
37. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
38. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
39. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.
Selim AG; El-Ayat G; Wells CA
J Clin Pathol; 2002 Jan; 55(1):14-6. PubMed ID: 11825917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]